Neuraxis (NRXS) Amortization of Deferred Charges (2022 - 2024)
Neuraxis (NRXS) posted Amortization of Deferred Charges of $40888.0 for Q3 2024, down 35.93% sequentially from $63817.0 in Q2 2024, and down 96.93% YoY from $1.3 million in Q4 2023.
Neuraxis (NRXS) Amortization of Deferred Charges (2022 - 2024) Analysis & Trends
Neuraxis has reported Amortization of Deferred Charges for 3 years, with the latest figure at $40888.0 in Q3 2024.
- Quarterly Amortization of Deferred Charges fell 96.93% year-over-year to $40888.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $126388.0 (down 97.41% YoY) and the FY2024 annual result came in at $126387.0, down 97.41% from the prior year.
- Amortization of Deferred Charges retreated to $40888.0 in Q3 2024 per NRXS's latest filing, from $63817.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.7 million in Q1 2023 and troughed at $12944.0 in Q2 2022.
- A 3-year average of $567438.3 and a median of $63817.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges surged 8203.89% in 2023, then sank 99.19% in 2024.
- Over 3 years, Amortization of Deferred Charges stood at $69962.0 in 2022, then jumped by 1802.5% to $1.3 million in 2023, then tumbled by 96.93% to $40888.0 in 2024.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $40888.0, $63817.0, and $21683.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 40,888.00 |
| Sep 30, 2024 | 40,888.00 |
| Jun 30, 2024 | 63,817.00 |
| Jun 30, 2024 | 63,817.00 |
| Mar 31, 2024 | 21,683.00 |
| Mar 31, 2024 | 21,683.00 |
| Sep 30, 2023 | 1.33 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 887,937.00 |
| Jun 30, 2023 | 887,937.00 |
| Mar 31, 2023 | 2.66 Mn |
| Mar 31, 2023 | 2.66 Mn |
| Dec 31, 2022 | 69,962.00 |
| Dec 31, 2022 | 69,962.00 |
| Sep 30, 2022 | 16,029.00 |
| Sep 30, 2022 | 16,029.00 |
| Jun 30, 2022 | 12,944.00 |
| Jun 30, 2022 | 12,944.00 |